This is interesting because I don't think I have seen test results correlated with disease presentation before.

-Linda Finn, Field biologist and lyme patient

On Fri, Apr 15, 2016 at 1:50 PM, linda finn <finn.linda@gmail.com> wrote:

RESEARCH ARTICLE

OPEN ACCESS

The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis

• M. M. G. LeeflangEmail author,
• C. W. Ang,
• J. Berkhout,
• H. A. Bijlmer,
• W. Van Bortel,
• A. H. Brandenburg,
• N. D. Van Burgel,
• A. P. Van Dam,
• R. B. Dessau,
• V. Fingerle,
• J. W. R. Hovius,
• B. Jaulhac,
• B. Meijer,
• W. Van Pelt,
• J. F. P. Schellekens,
• R. Spijker,
• F. F. Stelma,
• G. Stanek,
• F. Verduyn-Lunel,
• H. Zeller and
• H. Sprong

BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:140

DOI: 10.1186/s12879-016-1468-4

©  Leeflang et al. 2016

Received: 29 September 2015

Accepted: 14 March 2016

Published: 25 March 2016

Open Peer Review reports

Abstract

Background

Interpretation of serological assays in Lyme borreliosis requires an understanding of the clinical indications and the limitations of the currently available tests. We therefore systematically reviewed the accuracy of serological tests for the diagnosis of Lyme borreliosis in Europe.

Methods

We searched EMBASE en MEDLINE and contacted experts. Studies evaluating the diagnostic accuracy of serological assays for Lyme borreliosis in Europe were eligible. Study selection and data-extraction were done by two authors independently. We assessed study quality using the QUADAS-2 checklist. We used a hierarchical summary ROC meta-regression method for the meta-analyses. Potential sources of heterogeneity were test-type, commercial or in-house, Ig-type, antigen type and study quality. These were added as covariates to the model, to assess their effect on test accuracy.

Results

Seventy-eight studies evaluating an Enzyme-Linked ImmunoSorbent assay (ELISA) or an immunoblot assay against a reference standard of clinical criteria were included. None of the studies had low risk of bias for all QUADAS-2 domains. Sensitivity was highly heterogeneous, with summary estimates: erythema migrans 50 % (95 % CI 40 % to 61 %); neuroborreliosis 77 % (95 % CI 67 % to 85 %); acrodermatitis chronica atrophicans 97 % (95 % CI 94 % to 99 %); unspecified Lyme borreliosis 73 % (95 % CI 53 % to 87 %). Specificity was around 95 % in studies with healthy controls, but around 80 % in cross-sectional studies. Two-tiered algorithms or antibody indices did not outperform single test approaches.

Conclusions

The observed heterogeneity and risk of bias complicate the extrapolation of our results to clinical practice. The usefulness of the serological tests for Lyme disease depends on the pre-test probability and subsequent predictive values in the setting where the tests are being used. Future diagnostic accuracy studies should be prospectively planned cross-sectional studies, done in settings where the test will be used in practice.

http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1468-4